Welcome to our dedicated page for Sarepta Therapeutics, news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics, stock.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a pioneering biopharmaceutical company primarily engaged in the discovery and advancement of RNA-targeted therapeutics. Headquartered in Cambridge, Massachusetts, Sarepta is dedicated to developing innovative treatments for a range of rare, infectious, and other challenging diseases.
Core Focus: Sarepta’s primary focus is on Duchenne Muscular Dystrophy (DMD), a severe type of muscular dystrophy. The company's lead product candidate, eteplirsen, is designed to skip exon 51 and potentially modify the progression of DMD. Alongside eteplirsen, Sarepta is working on other DMD drug candidates that target different exons.
Innovative Technology: The company leverages proprietary RNA-targeted technology platforms to create novel pharmaceuticals. This technology is pivotal in addressing diseases with high unmet medical needs.
Therapeutic Pipeline:
- DMD Program: Focused on rapidly advancing exon-skipping drug candidates.
- Infectious Diseases: Developing treatments for drug-resistant bacteria and other rare infectious diseases.
Financial Condition and Partnerships: Sarepta collaborates with third-party contractors for the manufacturing of its product candidates. This strategic approach allows the company to focus on innovation and development while ensuring efficient production processes. Despite most of its product candidates being in early developmental stages, Sarepta continues to secure funding and partnerships to support its ambitious research and development goals.
For more information, visit their official website at www.sarepta.com.
Sarepta Therapeutics (NASDAQ:SRPT) announced on February 28, 2022, that it granted equity awards to 14 newly hired individuals as part of its 2014 Employment Commencement Incentive Plan. This grant involved options for 13,625 shares and 6,950 restricted stock units (RSUs). The options have an exercise price of $76.61 per share, equating to the closing price on the Grant Date. Vesting for options occurs over four years, while RSUs vest yearly over the same period, contingent upon continued employment.
Sarepta Therapeutics (NASDAQ:SRPT) will announce its fourth quarter and full-year 2021 financial results on March 1, 2022, after market close. The company will host a conference call at 4:30 p.m. E.T. to discuss these results and provide a corporate update. Interested parties can join the call by dialing specific numbers for domestic and international callers. Sarepta is focused on precision genetic medicine for rare diseases and has over 40 programs in development aimed at treating Duchenne muscular dystrophy and limb-girdle muscular dystrophies.
Sarepta Therapeutics (NASDAQ: SRPT) has announced a collaboration with GenEdit to develop gene editing therapeutics targeting neuromuscular diseases. Utilizing GenEdit's NanoGalaxy platform, the partnership aims to create effective non-viral delivery systems for genetic medicines. Initial in vivo results show successful delivery to muscle tissue. Sarepta has exclusive rights to license up to four neuromuscular indications. The collaboration could yield up to $57 million in payments for GenEdit, alongside future royalties on product sales, marking a significant advancement in genetic medicine.
Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 35 new employees as an inducement to employment, approved by its Board's Compensation Committee. The awards, totaling options for 35,575 shares and 18,350 restricted stock units (RSUs), were made under the 2014 Employment Commencement Incentive Plan. The options have an exercise price of $71.57 per share, aligning with SRPT's closing price on January 31, 2022.
The options and RSUs will vest gradually over four years, contingent upon continued employment.
Sarepta Therapeutics (NASDAQ: SRPT) announced positive topline results from Part 2 of Study SRP-9001-102, a clinical trial for SRP-9001, a gene therapy for Duchenne muscular dystrophy (DMD). Participants treated with SRP-9001 scored 2.0 points higher on the North Star Ambulatory Assessment compared to matched controls (p=0.0009). The therapy demonstrated a strong safety profile with no new safety signals or serious adverse events. The study, presented at the J.P. Morgan Healthcare Conference, reinforces confidence in SRP-9001's potential as a disease-modifying treatment for DMD.
Sarepta Therapeutics (NASDAQ:SRPT) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, showcasing topline results from Part 2 of Study SRP-9001-102. This study focuses on the investigational gene therapy SRP-9001 for children aged 4 to 7 with Duchenne muscular dystrophy. The virtual presentation is scheduled for 10:30 a.m. E.T. and will include a Q&A session. The event can be accessed live on Sarepta's investor relations website, where it will also be archived for 90 days.
Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 25 new employees as a material inducement for employment, approved by its Compensation Committee on December 31, 2021. The awards included options to purchase 19,175 shares and 9,900 restricted stock units (RSUs). The stock options have an exercise price of $90.05, equal to the closing price on the Grant Date. The vesting schedule for the options and RSUs is structured to encourage long-term employment, with shares fully vesting by December 31, 2025.
Sarepta Therapeutics (NASDAQ:SRPT) announced the grant of equity awards on November 30, 2021, as part of its 2014 Employment Commencement Incentive Plan. These awards serve as a material inducement to the hiring of 35 employees. In total, the company granted options for 42,225 shares and 21,675 restricted stock units (RSUs). The options have an exercise price of $80.81 per share and vest over a four-year period. Sarepta focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, and currently supports over 40 development programs.
Sarepta Therapeutics (NASDAQ:SRPT) has announced a leadership transition, appointing Louise Rodino-Klapac, Ph.D., as head of research and development (R&D) effective immediately. She continues her role as chief scientific officer, following the departure of Gilmore O’Neill, who will serve as a consultant through March 31, 2022. Dr. Rodino-Klapac has been instrumental in the advancement of Sarepta’s gene therapy platform. Under O’Neill’s leadership, the R&D team achieved significant milestones, including the approval of RNA-based therapies for Duchenne muscular dystrophy and the initiation of pivotal trials.
Sarepta Therapeutics (NASDAQ:SRPT) has appointed Dr. Stephen L. Mayo, a distinguished protein engineering expert, to its Board of Directors effective immediately. Dr. Mayo, who currently holds a professorship at Caltech and serves on Merck's board, brings extensive scientific knowledge and business insights. The leadership highlights that Dr. Mayo's expertise will enhance Sarepta's capabilities as it advances its gene therapy pipeline. This strategic addition aims to bolster the company's position in genetic medicine for rare diseases.
FAQ
What is the current stock price of Sarepta Therapeutics, (SRPT)?
What is the market cap of Sarepta Therapeutics, (SRPT)?
What does Sarepta Therapeutics specialize in?
What is eteplirsen?
Where is Sarepta Therapeutics headquartered?
What kinds of diseases is Sarepta working on?
How does Sarepta manufacture its products?
What is the primary technology used by Sarepta?
Are Sarepta's products approved for use?
How can I find more information about Sarepta Therapeutics?
Is Sarepta involved in any partnerships?
What is the latest news about Sarepta Therapeutics?
